Articles tagged with Hepatitis
A study of 371 patients with autoimmune hepatitis (AIH) found that extrahepatic autoimmune diseases (EADs) are common, particularly Sjogren's syndrome and autoimmune thyroid disease. Patients with EADs had a poorer early treatment response but achieved comparable outcomes after six months.
A new analysis found that prescriptions for curable hepatitis C drugs have declined sharply in recent years, leaving millions without treatment. The researchers urge swift actions to deliver the drugs to those who need them, including increased screening and system-level changes.
Researchers compare viral and MASLD cirrhosis pathogenic mechanisms, identifying shared pathways and diagnostic differences. The study aims to establish a framework for prevention, diagnosis, treatment, and monitoring of MASLD cirrhosis.
A multicenter analysis of 920 patients with compensated cirrhosis found that interferon therapy was not associated with a higher risk of serious complications compared to standard treatment. Milder side effects were more common and required closer monitoring.
A recent study found that prescriptions for direct-acting antivirals (DAAs) for hepatitis C increased rapidly after their introduction but declined sharply over time. As a result, many curable patients remain untreated, with treatment levels below national elimination targets.
A drug already in clinical trials for hepatitis C has been found to also prevent hepatitis E virus replication, offering new hope for a treatment option. The discovery was made using a library of nucleotide/nucleoside analogues and preclinical models.
This study reveals that p62-dependent protein aggregates protect liver cells against severe alcohol damage, providing a new perspective on toxic protein accumulation. The researchers found that the formation of these aggregates is not harmful but rather an adaptive response to chronic alcohol stress.
A network of genes connected to the nervous and immune systems can predict liver cancer risk, fatigue, and depression from viral hepatitis infection. The neuroimmunoma biomarker may monitor disease progression and indicate possible psychiatric complications.
Scientists at Scripps Research have engineered a stabilized version of the Hepatitis C virus's E1E2 glycoprotein complex, paving the way for a new nanoparticle-based vaccine candidate. The approach uses self-assembling protein nanoparticles to display the stable proteins in a manner that amplifies the immune response.
A family medicine interdisciplinary team improved hepatitis C virus treatment outcomes by streamlining medication access and reducing administrative burdens. The team's strategy, implemented at an urban clinic in Ohio, resulted in a significant reduction of treatment delays from over 6 months to under 2 months.
A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.
A study found that hepatitis C treatment with direct-acting antivirals (DAAs) improves immune function in individuals co-infected with HIV and HCV, even in those with advanced liver disease. The treatment resulted in significant declines in inflammation and liver damage markers.
The Hepatitis E virus has been found to be transmissible between rats and humans, with cases reported in Germany. The virus is primarily transmitted through contaminated food products from pigs and game animals, but its transmission via rat feces is still being investigated.
Leading experts urge universal hepatitis B vaccination for all newborns in the US, citing a 95% decline in infant infections since 1991. The policy has prevented an estimated one million hospitalizations and 90,000 deaths.
Autoimmune hepatitis is often associated with other autoimmune conditions, including thyroid disease, type 1 diabetes, inflammatory bowel disease, and rheumatologic disorders. The study highlights the need for precise diagnostic criteria and interdisciplinary management strategies to optimize outcomes in patients with multi-organ autoi...
This study found that mesaconate effectively mitigates autoimmune hepatitis by reducing inflammatory responses, oxidative stress, and apoptosis. MSA pretreatment also downregulates IFN-γ expression and inhibits the JAK1/2–STAT1 signaling pathway.
This review synthesizes current knowledge on khat-associated autoimmune hepatitis, establishing a causal link and guiding clinical management. Khat use disrupts immune tolerance, leading to a chronic inflammatory state and the development of AIH-like phenotype in susceptible individuals.
A global systematic review and meta-analysis of hepatitis B care found significant drop-offs in diagnosis, treatment initiation, and long-term retention across 50 countries. Decentralized, integrated models are needed to improve patient engagement and meet the WHO's 2030 elimination goals.
The European Union has launched a new toolkit to help eliminate viral hepatitis B and C in prisons across Europe. The toolkit provides practical tools and guidance for implementing interventions in prisons, with the goal of reducing transmission rates and promoting public health.
A nationwide study in Ukraine found substantial lifetime exposure to hepatitis B and C viruses, with significant ongoing circulation among the population. The study emphasizes the need for hepatitis B vaccination among infants and risk groups, as well as regular screening, treatment, and awareness-raising efforts.
Researchers argue that hepatitis B treatment should be expanded to include more people, as current drugs are safe and effective in slowing disease progression and reducing transmission. By treating more people earlier, the net disease and death rate can be significantly reduced.
Researchers used machine learning to predict patient outcomes in hospitalized cirrhosis patients, outperforming traditional methods. The study found that AI can help hospital teams triage and prioritize patients more effectively.
Researchers report a new class of drugs, called RNA interference therapeutics, that represent a major advancement in treating chronic HBV infections. These drugs can silence the virus and help reinvigorate the immune response, bringing us closer to a functional cure.
The study found that acute hepatitis E incidence and Disability-Adjusted Life Years (DALYs) increased globally from 1990 to 2021, with a slight rise in age-standardized rates. The number of incident cases is expected to continue increasing up to 2030.
The study found that elderly patients with acute hepatitis E infection have distinct gut microbiota compositions compared to healthy controls. The relative abundance of Bacteroides fragilis was significantly associated with disease outcomes, including self-healing and non-self-healing cases. This suggests a potential role for Bacteroid...
Recent advancements have identified several immunomodulators with promising roles in AIH treatment, including MMF, tacrolimus, sirolimus, infliximab, rituximab, and belimumab. These agents target specific immune pathways and have shown efficacy in achieving biochemical and histological remission.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
A new study found that routine testing for multiple infectious diseases among migrants can identify key infections earlier, improving health outcomes and reducing onward transmission. The Leicester screening programme, which tested 4004 migrant patients, revealed new diagnoses of TB, Hepatitis B and C, and HIV.
A global study found that pentoxifylline has no mortality benefit in patients with severe alcohol-associated hepatitis and acute kidney injury. The study, which included 525 patients across 20 centers from eight countries, reaffirmed previous findings that cast doubt on the efficacy of pentoxifylline in alcoholic hepatitis.
A new study reveals that YTHDF1 plays a crucial role in suppressing immune-mediated liver injury and modulating inflammatory responses. YTHDF1 deficiency exacerbates liver damage, inflammation, and proinflammatory cytokine production.
A study found that patients with AMA/anti-sp100/anti-gp210 positivity and elevated liver enzymes can manifest conditions beyond primary biliary cholangitis. Etiological treatments improved or resolved cholestatic biochemistry in these patients, justifying their initiation over ursodeoxycholic acid therapy.
Researchers from UNIGE-HUG Centre and MSF successfully demonstrated the effectiveness of a hepatitis E vaccine in an outbreak in Bentiu, South Sudan. The study showed that two doses of the vaccine reduced the incidence of the disease and provided protection against severe symptoms.
Researchers have discovered that AHCC suppresses liver fibrosis by inhibiting the activation of hepatic stellate cells through two channels. Early administration of AHCC may hold the key to preventing the onset of cirrhosis, a potentially fatal condition.
A study by University of Barcelona researchers found a close molecular similarity between wild boar and human hepatitis E virus strains. The researchers recommend avoiding contact with wild boars, washing hands after contact, and taking precautions in areas frequented by pets to prevent transmission.
Hepatitis E viruses can directly infect nerve cells, which are unable to protect themselves due to a low immune response. This discovery may explain the neurological effects of HEV infections.
Recent advancements in AIH pathogenesis have paved the way for novel therapeutic strategies, including treatments targeting the gut-liver axis and immune system dysregulation. Emerging biologics and immune-modulating drugs show promise in achieving biochemical remission in refractory cases.
Researchers from the University of Zurich have discovered a link between hepatitis E and kidney damage, finding that viral envelope-antibody complexes can accumulate in kidney filters and cause glomerulonephritis. The study uses tissue samples from patients to understand the disease mechanism.
The GALAD algorithm combines AFP, AFP-L3, and PIVKA-II for HCC detection. Combining GAAD, GALAD, or PIVKA-II with ultrasound improves diagnostic efficiency compared to recommended strategies.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
Researchers at Ohio State University discovered that a strain of rat hepatitis E can infect and spread among pigs, raising concerns about the potential transmission of the virus to humans. The study found that infected pigs shed the virus in their feces, highlighting the need for improved food safety procedures.
The study evaluated 7 guidelines for the diagnosis and treatment of HEV infection, finding significant variability in quality and consistency. The guidelines scored poorly in areas such as stakeholder involvement, rigor of development, and applicability, highlighting the need for improvements.
A research group developed a long-acting artificial hepatocyte growth factor (HGF) mimetic molecule using cyclic peptides and protein engineering. The molecule improved liver fibrosis, lipid accumulation, and inflammation in a mouse model with non-alcoholic steatohepatitis (NASH), providing an option for NASH therapeutics.
Autoimmune liver diseases like AIH, PBC, and PSC exhibit distinct cellular targets and inflammatory profiles. Single-cell RNA sequencing and spatial transcriptomics provide new insights into their pathogenesis and potential treatment strategies.
Researchers at Ohio State University discovered the hepatitis E virus is associated with sperm in pigs, suggesting a possible link to male infertility and sexual transmission. The virus was found to circulate in blood and shed in feces, with viral particles present on the head of sperm cells that can infect human liver cells.
Researchers analyzed virus populations from a chronically infected patient and found that human-derived RNA fragments helped the virus replicate better in cell culture. The incorporation of host RNA into the viral genome may serve as a biomarker for early detection of chronic infections.
Researchers in South Korea have detected the first hepatitis E virus from urban Norway rats, raising concerns about potential human transmission. The study found that 4.4% of examined rats carried the virus, which is linked to symptoms like fever, fatigue, and jaundice in humans.
A University of Sydney study sheds light on the 2022 child hepatitis outbreak, finding that 'helper virus' infections were likely the cause. The study reveals that over 3,000 cases were reported globally, with six percent requiring liver transplants.
Researchers detected nearly 73% of hepatitis E virus RNA in wastewater samples from sewage treatment plants. High-throughput sequencing revealed genetic variants that could indicate drug resistance, posing a challenge for treatment.
Researchers are exploring immune-based therapies and curative combinations to overcome HBV's unique biology and immunosuppression. Ongoing clinical trials aim to develop a functional cure with finite treatment duration.
A new study published in Exp. Mol. Med. has identified Thrap3 as a key player in exacerbating non-alcoholic fatty liver disease (NAFLD) by inhibiting AMPK, a crucial regulator of fat metabolism. Inhibiting Thrap3 expression presents a promising avenue for treating NAFLD.
A study published in Hepatology reveals that abnormal pre-mRNA splicing is associated with liver disease caused by excessive alcohol consumption. The researchers propose targeting specific splicing factors as a novel approach to mitigate the disease.
Hospital admissions for alcohol-related hepatitis increased dramatically during the pandemic, particularly among younger patients and women. Researchers found a 12.4% rise in cases in 2020 compared to 2019 levels.
A case of echovirus 11-induced hepatitis in Italian male twins has been reported, showing a close genetic relation to strains found in France among neonates. The study highlights the importance of rapid recognition and timely treatment to ensure survival, and suggests potential host genetic predisposition in male and twin categories.
Researchers link acute severe hepatitis in children to co-infections with multiple common viruses, including AAV2. The study suggests that getting more than one infection may have made children vulnerable to severe hepatitis.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...
Researchers have identified a blood protein snapshot that documents changes in patients with severe liver disease caused by heavy drinking, potentially leading to a simple blood test for diagnosis and treatment monitoring.
Researchers identified HCirV-1 in a patient with unexplained chronic hepatitis, demonstrating its role in liver damage. After treatment, the patient's liver enzymes returned to normal levels, indicating the end of hepatic cytolysis.
A team of researchers from MedUni Vienna has identified the polymeric immunoglobulin receptor (pIgR) as a key player in protecting against alcohol-induced liver damage. The study found that pIgR-mediated secretion of antibodies in the intestines helps to prevent bacterial translocation and inflammation in the liver.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.